Maximize clinical success rates
by boosting productivity and developability
Benefit from our royalty-free approach to speed up clinical development
Fast cell line and protocol transference to your CMO partners for cGMP bioproduction
Minimize production risks thanks to our extensive early testing of antibody candidates
Proprietary CHO, CHO-S, CHO-DG44, HEK293 or even your preferred cell line… Get a service adapted to your requirements!
Ensure your cell line generates the highest possible yields thanks to our proven amplification protocols
Plan for the long-term and secure your investments by choosing a stable cell line development service with strong guarantees
500+ monoclonal antibodies developed, 100+ stable cell lines generated, 28+ years of experience in protein production. Choose a leading bioproduction company.
Stay in complete control of your project thanks to our milestone-oriented approach for better flexibility
After stable cell line development:
CHO-S, CHO-DG44, CHO-K1, proprietary GS-CHO cell line (upcoming) among others
HEK293F, HEK293E, among others
Baby hamster kidney (BHK), mouse myeloma (NS0) cells, Per.C6, among others
Most mammalian cell lines can either be selected using metabolic or antibiotic markers. The most widely used markers for recombinant monoclonal antibody production are metabolic, including:
Metabolic selection markers have remained the gold standard for stable cell line generation. This preference can be explained by the versatility of these systems. Particularly in CHO cells, the presence of increasing concentrations of MTX/MSX is unknown to result in the amplification of antibody encoding genes. Consequently, this leads to a significant increase in production yield in comparison to other recombinant expression systems.
However, our focus remains on flexibility. For this reason we offer a vast choice of selection systems and cell lines allowing us to adapt the process of stable cell line generation to your unique requirements and needs.
Discuss your project with our PhD account managers to receive a tailor-made proposal:
Antibody genes were optimized for expression in CHO cell lines, synthesized, and subcloned into our proprietary transient expression system.
CHO-K1 cells (30 ml) were transiently transfected, transient pools were grown in 30 ml, and antibody purification was performed using protein G resin.
3 positive stable pools were further characterized in fed-batch experiments and antibodies characterized by SEC-HPLC to confirm purity and detect potential aggregation
95% of biologics under development fail to reach the market or clinic due to undetected developability issues. Early testing or screening has thus become crucial to overcome low success rates and minimize development risks. Producing monoclonal antibodies in vitro via transient systems is still the best way to produce small amounts of antibodies for measuring:
Detectable problems at this stage can be corrected by additional engineering of antibody leads. These engineering efforts, although laborious, can save considerable costs and time on the long run to license your therapeutic antibodies.
To learn more about stable cell line development, visit our frequently asked questions (FAQs) page. On this page, we cover all seminal principles and knowledge regarding monoclonal antibody production in stable cells and provide detailed insights into ProteoGenix’s unique platform for stable cell line development.